EDN1 and prostate carcinoma: In 2007, Gorada et al assessed 120 cases of prostate cancer and found immunoreactivity to endothelin-1 in 72% of patients as well as a positive relationship between endothelin-1 expression and PSA levels but not with tumor Gleason score.